Compare DGII & CDNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DGII | CDNA |
|---|---|---|
| Founded | 1985 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.6B |
| IPO Year | 1995 | 2007 |
| Metric | DGII | CDNA |
|---|---|---|
| Price | $78.11 | $64.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | ★ $48.80 | $28.00 |
| AVG Volume (30 Days) | 312.0K | ★ 1.1M |
| Earning Date | 05-06-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.05 | N/A |
| EPS | 1.00 | ★ 2.13 |
| Revenue | ★ $430,221,000.00 | $48,324,000.00 |
| Revenue This Year | $18.71 | $16.01 |
| Revenue Next Year | $7.22 | $11.31 |
| P/E Ratio | $76.75 | ★ $28.81 |
| Revenue Growth | 1.46 | ★ 18.93 |
| 52 Week Low | $34.41 | $13.95 |
| 52 Week High | $86.84 | $63.09 |
| Indicator | DGII | CDNA |
|---|---|---|
| Relative Strength Index (RSI) | 64.66 | 78.93 |
| Support Level | $64.63 | $17.26 |
| Resistance Level | $86.43 | N/A |
| Average True Range (ATR) | 2.29 | 2.71 |
| MACD | 1.00 | 0.78 |
| Stochastic Oscillator | 99.76 | 93.63 |
Digi International Inc is a Minnesota corporation that provides business and mission-critical Internet of Things (IoT) connectivity products and services. It operates through two segments: IoT Products & Services, which supports OEMs, enterprise, and government customers in deploying secure IoT connectivity solutions, and IoT Solutions, consisting of SmartSense and its Managed Network-as-a-Service (MNaaS) business offering wireless temperature and condition-based monitoring, employee task management, label printing, and other services. The company generates the majority of its revenue from the IoT Products & Services segment and mainly from the United States, with a presence in Europe, the Middle East and Africa, and the Rest of the world.
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.